AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34873221 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) - biceps curl and squat training, 2 days/week, 60-70% repetition maximum, 3-4 sets, 120 s rest intervals, reps until muscular failure
Number of subjects: 18
Study 34873221 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) - biceps curl and squat training
Number of subjects: 18
Study 34873345 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib, a selective KIT D816V inhibitor, starting dose of 200 mg once daily
Number of subjects: 62
Study 34873345 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 62
Study 34873347 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib (BLU-285) at doses of 30-400 mg once daily
Number of subjects: 86
Study 34873347 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib (BLU-285)
Number of subjects: 86
Study 34873419 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful parenting workshop
Number of subjects: 54
Study 34873419 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 54
Study 34873795 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP telemonitoring
Number of subjects: 555
Study 34873921 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized common carotid artery IMT
Number of subjects: 1309
Study 34873975 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib prior to chemotherapy
Number of subjects: 0
Study 34874228 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) including modified GA (mGA) assessing comorbidities, medications, nutritional status, basic- and instrumental activities of daily living (IADL), mobility, falls, cognition, and depressive symptoms.
Number of subjects: 301
Study 34874228 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status and IADL function as assessed by mGA.
Number of subjects: 301
Study 34874345 — intervention group
Group type: EXPERIMENTAL
Intervention: 360°-CZT camera
Number of subjects: 92
Study 34874345 — intervention group
Group type: COMPARATOR
Intervention: Conventional camera
Number of subjects: 92
Study 34874404 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led asthma self-management program
Number of subjects: 320
Study 34874404 — intervention group
Group type: COMPARATOR
Intervention: Adult-led asthma self-management program (Control)
Number of subjects: 320
Study 34874509 — intervention group
Group type: EXPERIMENTAL
Intervention: LA strain during conduit phase (LAScd)
Number of subjects: 79
Study 34874509 — intervention group
Group type: EXPERIMENTAL
Intervention: LA strain during reservoir phase (LASr)
Number of subjects: 79
Study 34874509 — intervention group
Group type: EXPERIMENTAL
Intervention: LAScd cutoff value of -11%
Number of subjects: 79
Study 34874509 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day cumulative risk of AF with LAScd > -11%
Number of subjects: 79
Study 34874514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg
Number of subjects: 2247
Study 34874514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2247
Study 34874514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant (50 mg and 100 mg) in long-term safety trial
Number of subjects: 2247
Study 34874567 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-sensitization
Number of subjects: 0
Study 34874751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk SCU HB
Number of subjects: 35
Study 34874751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-risk SCU HB
Number of subjects: 35
Study 34874751 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk SCU HB
Number of subjects: 35
Study 34874751 — intervention group
Group type: COMPARATOR
Intervention: Low-risk non-SCU HB
Number of subjects: 35
Study 34874751 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-risk non-SCU HB
Number of subjects: 35
Study 34874751 — intervention group
Group type: COMPARATOR
Intervention: High-risk non-SCU HB
Number of subjects: 35
Study 34874836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Number of subjects: 3164
Study 34874888 — intervention group
Group type: EXPERIMENTAL
Intervention: blended cognitive behavioral therapy (bCBT)
Number of subjects: 240
Study 34874892 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic risk alert
Number of subjects: 159
Study 34874892 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced education
Number of subjects: 159
Study 34874892 — intervention group
Group type: EXPERIMENTAL
Intervention: Building self-efficacy
Number of subjects: 159
Study 34874892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering motivation
Number of subjects: 159
Study 34874892 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving self-regulation
Number of subjects: 159
Study 34874892 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 159
Study 34875023 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT with lymphodepleting, reduced intensity regimen including CYC, fludarabine, and rituximab.
Number of subjects: 8
Study 34875023 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT with lymphodepleting, reduced intensity regimen.
Number of subjects: 8
Study 34875086 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with primary social anxiety disorder or primary BDD
Number of subjects: 30
Study 34875086 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 30
Study 34875106 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant monotherapy
Number of subjects: 929
Study 34875106 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic monotherapy
Number of subjects: 929
Study 34875106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antidepressant plus antipsychotic
Number of subjects: 929
Study 34875106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 929
Study 34875107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤2 years
Number of subjects: 25
Study 34875107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 25
Study 34875111 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose thromboprophylaxis
Number of subjects: 165
Study 34875111 — intervention group
Group type: COMPARATOR
Intervention: Intermediate-dose thromboprophylaxis
Number of subjects: 165
Study 34875258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition white-light imaging (HDWLI) + virtual chromoendoscopy (VCE)
Number of subjects: 400
Study 34875258 — intervention group
Group type: COMPARATOR
Intervention: Dye-based chromoendoscopy (DBC)
Number of subjects: 400
Study 34875258 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of a demarcated area (DA)
Number of subjects: 400
Study 34875458 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE-MS technique
Number of subjects: 515
Study 34875458 — intervention group
Group type: EXPERIMENTAL
Intervention: SPACE-MS metrics (including anisotropy, planarity, sphericity, neuraxis caudality index)
Number of subjects: 515
Study 34875458 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor and cognitive disability scales assessments
Number of subjects: 515
Study 34875458 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural brain MRI (1.5/3.0 T)
Number of subjects: 515
Study 34875909 — intervention group
Group type: COMPARATOR
Intervention: Cluster 1 (optimal oral health and preserved masticatory capacity)
Number of subjects: 5294
Study 34875909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (moderate oral health and moderately impaired masticatory capacity)
Number of subjects: 5294
Study 34875909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (poor oral health and severely impaired masticatory capacity)
Number of subjects: 5294
Study 34876196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 284
Study 34876196 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) antibiotics
Number of subjects: 284
Study 34876207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (group 1) for patients with positive high-sensitive troponin T (HsTnT) status
Number of subjects: 0
Study 34876207 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (group 2) for patients with negative HsTnT status
Number of subjects: 0
Study 34876207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 3) for patients with negative HsTnT status
Number of subjects: 0
Study 34876283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (N = 84)
Number of subjects: 250
Study 34876283 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (N = 166)
Number of subjects: 250
Study 34876283 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement
Number of subjects: 250
Study 34876381 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque rupture
Number of subjects: 198
Study 34876396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloud DX Vitaliti continuous vital signs monitor (CVSM) for continuous noninvasive blood pressure (cNIBP) measurements
Number of subjects: 20
Study 34876396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloud DX Vitaliti continuous vital signs monitor (CVSM)
Number of subjects: 20
Study 34876408 — intervention group
Group type: EXPERIMENTAL
Intervention: CART therapy targeting BCMA, fractioned dose of 3×10
Number of subjects: 1
Study 34876409 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg every 3 weeks
Number of subjects: 121
Study 34876419 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric toddler milk with 1.5 g/100 kcal protein
Number of subjects: 1618
Study 34876419 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric toddler milk with 6.15 g/100 kcal protein (control)
Number of subjects: 1618
Study 34876420 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin hydrochloride, daily starting from 5 days prior to surgery, on the day of surgery, and for 1 day following surgery.
Number of subjects: 634
Study 34876420 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule matching the active study drug, daily starting from 5 days prior to surgery, on the day of surgery, and for 1 day following surgery.
Number of subjects: 634
Study 34876429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)-based mobile app
Number of subjects: 0
Study 34876429 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 34876434 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg ATG
Number of subjects: 114
Study 34876434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 34876434 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG (0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg)
Number of subjects: 114
Study 34876457 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Maternity Waiting Home (MWH) model
Number of subjects: 2381
Study 34876457 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 2381
Study 34876622 — intervention group
Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome patients with acute neurological disorders
Number of subjects: 2402
Study 34876622 — intervention group
Group type: COMPARATOR
Intervention: Takotsubo syndrome patients without acute neurological disorders
Number of subjects: 2402
Study 34877470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 17
Study 34877470 — intervention group
Group type: COMPARATOR
Intervention: Non-FMT treatment
Number of subjects: 17
Study 34877629 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS-generated STOPP/START signals
Number of subjects: 826
Study 34877629 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPP signals
Number of subjects: 826
Study 34877629 — intervention group
Group type: EXPERIMENTAL
Intervention: START signals
Number of subjects: 826
Study 34877629 — intervention group
Group type: COMPARATOR
Intervention: STOPP signals in Ireland
Number of subjects: 826
Study 34877629 — intervention group
Group type: COMPARATOR
Intervention: START signals in Ireland
Number of subjects: 826
Study 34877629 — intervention group
Group type: COMPARATOR
Intervention: STOPP signals in the Netherlands
Number of subjects: 826
Study 34877629 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPP signals in surgical wards
Number of subjects: 826
Study 34877761 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels in healthy children
Number of subjects: 2455
Study 34877828 — intervention group
Group type: EXPERIMENTAL
Intervention: High pre-/high post-PCI FFR group
Number of subjects: 1479
Study 34877828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-/high post-PCI FFR group
Number of subjects: 1479
Study 34877828 — intervention group
Group type: EXPERIMENTAL
Intervention: High pre-/low post-PCI FFR group
Number of subjects: 1479
Study 34877828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-/low post-PCI FFR group
Number of subjects: 1479
Study 34877828 — intervention group
Group type: COMPARATOR
Intervention: Low pre-PCI FFR group
Number of subjects: 1479
Study 34877828 — intervention group
Group type: COMPARATOR
Intervention: High pre-PCI FFR group
Number of subjects: 1479
Study 34877830 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary ultrasonography (US) for nodal evaluation
Number of subjects: 0
Study 34877830 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized imaging protocol and criteria for evaluation of axillary lymph nodes
Number of subjects: 0
Study 34877867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-PTX, S-1, and sintilimab (8 cycles, Nab-PTX on days 1 and 8, S-1 on days 1 to 14, sintilimab on day 1, maintenance for up to 12 months)
Number of subjects: 0
Study 34878173 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 1615
Study 34878173 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 1615
Study 34878173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 1615
Study 34878437 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (five-strain probiotic capsules, 1.2 × 10^10 CFUs/d for 8 weeks)
Number of subjects: 20
Study 34878437 — intervention group
Group type: COMPARATOR
Intervention: Control (no probiotics)
Number of subjects: 20
Study 34878624 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg twice daily with estradiol 1 mg/norethindrone acetate 0.5 mg daily
Number of subjects: 2168
Study 34878892 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging-guided adrenalectomy
Number of subjects: 231
Study 34878892 — intervention group
Group type: COMPARATOR
Intervention: Adrenal vein sampling
Number of subjects: 231
Study 34878898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead levels in quartile four (≥6.5 µg/dL)
Number of subjects: 2504
Study 34878898 — intervention group
Group type: COMPARATOR
Intervention: Lead levels in quartile one (<3.4 µg/dL)
Number of subjects: 2504
Study 34878959 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccine (QIV)
Number of subjects: 636
Study 34878991 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanManage smartphone-based interactive CRC self-management enhancement psychosocial program
Number of subjects: 5
Study 34879143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie
Number of subjects: 1102
Study 34879143 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube with stylet
Number of subjects: 1102
Study 34879299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined shear wave elastography (SWE) and strain elastography (SE)
Number of subjects: 1288
Study 34879299 — intervention group
Group type: COMPARATOR
Intervention: Routine B-mode breast ultrasound
Number of subjects: 1288
Study 34879299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SWE and SE
Number of subjects: 1288
Study 34879394 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotting factor concentrates (observed CVD incidence)
Number of subjects: 709
Study 34879394 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hemophilia treated on demand
Number of subjects: 709
Study 34879394 — intervention group
Group type: COMPARATOR
Intervention: Predicted CVD incidence based on QRISK2-2011 CVD risk model
Number of subjects: 709
Study 34879833 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 354
Study 34879833 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin
Number of subjects: 354
Study 34879833 — intervention group
Group type: EXPERIMENTAL
Intervention: Kynurenic acid (KA)
Number of subjects: 354
Study 34879833 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin (in combination with KA)
Number of subjects: 354
Study 34879854 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of placental biochemical and biophysical cardiovascular markers in the first and third trimesters of pregnancy.
Number of subjects: 440
Study 34879854 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal echocardiographic parameters assessed during pregnancy.
Number of subjects: 440
Study 34879854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal cardiac function evaluated in the third trimester of pregnancy.
Number of subjects: 440
Study 34879854 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of new cardiac biomarkers.
Number of subjects: 440
Study 34879862 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post-tetanic count 1-5)
Number of subjects: 556
Study 34879862 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade (tetanic count of four > 1)
Number of subjects: 556
Study 34879862 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intra-abdominal pressure (≥10 mmHg)
Number of subjects: 556
Study 34879862 — intervention group
Group type: COMPARATOR
Intervention: Low intra-abdominal pressure (<10 mmHg)
Number of subjects: 556
Study 34879862 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 556
Study 34879861 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS extinction and inattention subtest
Number of subjects: 118
Study 34879861 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS visual field subtest
Number of subjects: 118
Study 34879861 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS extinction and inattention item
Number of subjects: 118
Study 34879873 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising Together© (dyadic resistance training program)
Number of subjects: 10
Study 34880013 — intervention group
Group type: EXPERIMENTAL
Intervention: Single infusion of autologous ex vivo expanded regulatory T cells (Treg)
Number of subjects: 10
Study 34880087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical microstimulation (ICMS) delivered over a 2-year period.
Number of subjects: 1
Study 34880087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical microstimulation (ICMS) with varying pulse amplitudes (20 to 80 µA).
Number of subjects: 1
Study 34880087 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection thresholds estimated on a subset of electrodes.
Number of subjects: 1
Study 34880117 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESIs) for sciatica
Number of subjects: 346
Study 34880117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint (SIJ) injections
Number of subjects: 346
Study 34880117 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet interventions
Number of subjects: 346
Study 34880117 — intervention group
Group type: COMPARATOR
Intervention: All groups (combined)
Number of subjects: 346
Study 34880117 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 346
Study 34880620 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation (NMES)
Number of subjects: 40
Study 34880809 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Individual Cognitive Stimulation Program
Number of subjects: 0
Study 34880809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34881407 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Rapid Intubation Teams (ERIT)
Number of subjects: 117
Study 34881720 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp usage for COVID-19 content transmission
Number of subjects: 151
Study 34881720 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume of forwarded COVID-19 content
Number of subjects: 151
Study 34881720 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with COVID-19 content in personal chats
Number of subjects: 151
Study 34882037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 1216
Study 34882183 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored annular closure device
Number of subjects: 554
Study 34882183 — intervention group
Group type: COMPARATOR
Intervention: Lumbar microdiscectomy only (control group)
Number of subjects: 554
Study 34882311 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 3406
Study 34882311 — intervention group
Group type: COMPARATOR
Intervention: Non-selective NSAIDs
Number of subjects: 3406
Study 34882311 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 3406
Study 34882570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal racemic ketamine hydrochloride administered twice per week for 4 weeks (8 sessions)
Number of subjects: 25
Study 34882570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal racemic ketamine hydrochloride
Number of subjects: 25
Study 34882570 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Number of subjects: 25
Study 34882589 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (3 µg intramuscular doses, two doses 28 days apart)
Number of subjects: 3371
Study 34882589 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine
Number of subjects: 3371
Study 34882591 — intervention group
Group type: EXPERIMENTAL
Intervention: Damage-control surgery (DCS)
Number of subjects: 2174
Study 34882591 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (CS)
Number of subjects: 2174
Study 34882631 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (once a week for 10 weeks)
Number of subjects: 9